Share
GvHD Hub
How does real-world evidence complement RCTs, and why is it important for small patient populations?
•
Real-world evidence (RWE) and randomized controlled trial (RCT) data each have both advantages and disadvantages, and they can be complementary. In general, outcomes of real-world studies are given lower credibility compared with RCT research, which is characterized as having the highest reliability. However, real-world studies can be particularly advantageous in specific patient populations, for instance in chronic graft-versus-host disease (cGvHD), which may have a lack of RCT data.
The GvHD Hub spoke to Steven Pavletic, National Cancer Institute, Bethesda, US, about his perspectives on how RWE can complement RCTs, and why it may be important for small patient populations.
RCT vs RWE
- Data from RCTs are considered the ‘gold-standard’ for investigating the efficacy and safety of treatments, owing to the well-controlled, observational environment, with strict inclusion and exclusion criteria.
- A major challenge with RCT data is that they generally apply to a specific population of patients but may not be relevant for all individuals with the disease.
Ideally, RCTs and real-world studies should be developed to be complementary. For example, if an RCT investigates the efficacy of a drug, the real-world studies can focus on the epidemiology, effectiveness, safety, or costs of treatment related to that drug.
Real-world data in cGvHD
- cGvHD is heterogeneous in presentation, with variability in severity, organ involvement, and manifestations.
- It is important to identify less common adverse effects that may result from treatment in patients with varied clinical manifestations of cGvHD, which is not always possible in clinical trials.
- Therefore, further RWE and observational studies are needed to provide additional data on the safety and efficacy of treatments, particularly in cGvHD which can have distinct patient populations. However, these studies lack the consistency of RCTs, and caution should be used when interpreting results.
- Several recent prospective phase II/III studies have led to the approval of new agents for cGvHD, including ibrutinib, ruxolitinib, and belumosudil. In the case of belumosudil, real-world studies have consistently shown safety and effectiveness similar to the RCTs, which is encouraging for the broader cGvHD patient population.
- Both RWE and RCTs can be helpful tools for advancing clinical research and informing patient care, especially when considered together.
More episodes
View all episodes
What are the treatment options for chronic GvHD-associated fibrosis?
06:03|The GvHD Hub was pleased to speak with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What are the treatment options for chronic GvHD-associated fibrosis? In this interview, Cutler discusses the development and clinical impact of fibrotic manifestations in chronic graft-versus-host disease (cGvHD), and explores the U.S. Food and Drug Administration (FDA)-approved therapies, including ibrutinib, ruxolitinib, belumosudil, and axatalimab, and the differences in their mechanisms of actions that may influence their use in the treatment of fibrotic disease. He also considers how novel antifibrotic agents might be integrated into the management of fibrotic cGvHD in the future. This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.MSCs: From clinical trials to clinical practice
40:21|During the GvHD Hub Steering Committee Meeting in December 2025, key opinion leaders met to discuss the mechanism of action and clinical data supporting the use of mesenchymal stromal cells (MSCs) for the treatment of graft-versus-host disease (GvHD). The meeting opened with a presentation by Robert Zeiser and featured a discussion including Mohamad Mohty, Yi-Bin Chen, Daniel Wolff, Florent Malard, Corey Cutler, and Andrew Harris. During his presentation, Zeiser outlined the proposed mechanism of action of MSCs, describing how they promote an immunosuppressive and immunoregulatory environment. He explored the evolving clinical trial landscape of MSCs in the treatment of GvHD, beginning with the first reported use in 2004, and summarized key trial results leading to the approval of the MSC products remestemcel-L and JR-031. Zeiser highlighted the challenge of MSC product variability, which has contributed to heterogenous response rates across studies. He introduced MSC-Frankfurt am Main (FFM), an MSC product generated by pooling bone marrow-derived mononuclear cells from eight human leukocyte antigen (HLA)-disparate donors to reduce variability. He also explored MSC-FFM outcomes across real-world cohorts and presented the study designs of two ongoing phase II/III trials.This discussion topic is supported by Medac, who provided funding. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.Symposium | Early treatment strategies for SR-GvHD
36:28|The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD? Here, we share a presentation by Daniel Wolff, University Hospital Regensburg, DE, discussing the early treatment strategies for SR-GvHD. Wolff provided an overview of the treatment options for second-line treatment after steroids and subsequent advanced-line options, emphasizing that early detection of disease progression and sufficient treatment intervention are crucial, as advanced disease is often nonreversible. Wolff discussed response assessments to first-line steroid treatment and second-line treatments, and outlined the treatment options for patients with SR-cGvHD, including ruxolitinib, belumosudil, axatilimab, ibrutinib, and extracorporeal photopheresis. This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.Symposium | Quality of life and symptoms in cGvHD
20:39|The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD. Here, we share a presentation by Steven Pavletic, Bethesda, US, discussing quality of life and symptoms in cGvHD. Pavletic discussed the importance of the assessment of quality of life using patient-reported outcome measures (PROMs) in both clinical trials and clinical practice in cGvHD, outlining the frequently used PROMs in GvHD, including cGvHD-specific and dimension-specific measures. Pavletic highlighted that incorporation of PROMs into standard of care practice may ultimately lead to more tailored and effective clinical assessments. This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What are the treatment options for ruxolitinib-refractory acute GvHD?
06:50|The GvHD Hub was pleased to speak with Mohamad Mohty. We asked, What are the treatment options for ruxolitinib-refractory acute GvHD?In this interview, Mohamad Mohty discusses the evolving management of steroid-refractory acute GvHD, highlighting ruxolitinib as the standard of care and the importance of robust supportive measures. Mohty explores treatment options for ruxolitinib-refractory disease – including extracorporeal photopheresis, mesenchymal stromal cells, and emerging targeted approaches. Mohty highlights the value of referral to specialized centers and clinical trial enrolment as treatment shifts toward precision-guided, biology-driven strategies.This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.Symposium | The importance of real-world data in allogeneic stem cell transplantation: A focus on cGvHD
20:46|The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD? Here, we share a presentation by Mohamad Mohty, Sorbonne University Hôpital Saint-Antoine, Paris, FR, discussing the importance of real-world data (RWD) in allogeneic stem cell transplantation with a focus on cGvHD.Mohty provided an overview of RWD, including their use in regulatory decision-making, types of RWD, study designs, and limitations. Mohty explored whether results of pivotal clinical trial results can be reproduced with RWD, highlighting the consistent outcomes observed in a French compassionate use program of belumosudil.This educational resource is independently supported by Sanofi.All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What are the current treatment options for steroid-refractory chronic GvHD?
08:32|The GvHD Hub was pleased to speak with Robert Zeiser. We asked, What are the current treatment options for steroid-refractory chronic GvHD (SR-cGvHD)? In this interview, Zeiser explores the current treatment options for SR-cGvHD, such as ruxolitinib, ibrutinib, belumosudil, and axatilimab, and discusses the different mechanisms of action involved in targeting distinct pathways involved in cGvHD pathogenesis. Zeiser notes that future directions may focus on identifying optimal combination therapies for patients with SR-cGvHD. This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What are the major challenges in the treatment of SR-GvHD, and how can clinicians overcome these?
03:56|Despite advances in preventing chronic graft-versus-host disease (GvHD), transplant recipients continue to be affected, with steroid-refractoriness associated with significantly increased morbidity and mortality.1The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What are the major challenges in the treatment of steroid-refractory GvHD (SR-GvHD), and how can clinicians overcome these?This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.How can measurement of QoL and use of PROs be improved in cGvHD?
25:40|During the GvHD Hub Steering Committee Meeting on May 12, 2025, key opinion leaders met to discuss how to improve measurement of quality of life (QoL) and use of patient-reported outcomes (PROs) in cGvHD. The discussion was preceded by a presentation by Mohamad Mohty, and the discussion featured Nico Gagelmann, Bipin Savani, Ali Bazarbachi, Corey Cutler, and Andrew Harris. Mohty began by explaining the necessity of measuring QoL in patients with graft-versus-host disease (GvHD) and the current use of PROs in trials and clinical practice. During the discussion, the steering committee members provided insight into the difficulties implementing QoL assessment in clinical practice, and potential solutions.This independent educational activity is supported by Sanofi. All content was developed independently. The funder was allowed no influence on the content of this activity.